Biotech Growth Trust PLC (The) Edison issues review on The Biotech Growth Trust
April 04 2022 - 2:01AM
RNS Non-Regulatory
TIDMBIOG
Biotech Growth Trust PLC (The)
04 April 2022
London, UK, 4 April 2022
Edison issues review on The Biotech Growth Trust (BIOG)
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu at
healthcare specialist OrbiMed Capital, and benefits from OrbiMed's
presence in 11 offices across the globe. While the trust has had a
weak period of absolute and relative performance over the last 12
months, the manager believes that the focus on emerging biotech
(smaller-cap) and emerging market biotech stocks is the correct
strategy; following this approach proved very successful for BIOG's
FY21 results. Investors are currently not focusing on the biotech
sector's strong fundamentals, and the sell-off since early-February
2021 may have created a very attractive entry point for those
willing to look beyond the current cyclical/value stock market
leadership.
Perhaps reflecting weakness in the biotech sector, BIOG's
valuation has been volatile since the middle of 2021. Its current
6.6% discount to cum-income NAV compares with a range of a 3.3%
premium to an 11.5% discount over the last 12 months. Over the last
one, three, five and 10 years the trust's average discounts are
2.5%, 4.3%, 5.0% and 4.6%, respectively.
Click here to view the full report or here to sign up to receive
research as it is published.
All reports published by Edison are available to download free
of charge from its website
www.edisongroup.com
About Edison: E dison is a leading research and investor
relations consultancy, connecting listed companies to the widest
pool of global investors. By focusing on the volume and quality of
investors reached - across institutions, family offices, wealth
managers and retail investors - Edison can create and gauge intent
to purchase, even in the darkest pools of capital, and then make
introductions via non-deal roadshows, events or virtual
meetings.
Having been the first in-market 17 years ago, Edison now has
more than 100 analysts covering every economic sector.
Headquartered in London, Edison also has offices in New York,
Frankfurt, Amsterdam and Tel Aviv and a presence in Athens,
Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct
Authority .
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
For more information, please contact Edison:
Mel Jenner +44 (0)20 3077 5700
investmenttrusts@edisongroup.com
Sarah Godfrey +44 (0)20 3077 5700
investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAPLFEAPAEEA
(END) Dow Jones Newswires
April 04, 2022 02:01 ET (06:01 GMT)
Biotech Growth (LSE:BIOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biotech Growth (LSE:BIOG)
Historical Stock Chart
From Sep 2023 to Sep 2024